179 related articles for article (PubMed ID: 17986279)
21. Results of rosiglitazone therapy in patients with thyroglobulin-positive and radioiodine-negative advanced differentiated thyroid cancer.
Kebebew E; Lindsay S; Clark OH; Woeber KA; Hawkins R; Greenspan FS
Thyroid; 2009 Sep; 19(9):953-6. PubMed ID: 19678746
[TBL] [Abstract][Full Text] [Related]
22. Aspects of timing and selection of cases in radioiodine therapy and percutaneous irradiation of well differentiated carcinoma of the thyroid.
Wiebe V; Schneider C; Franke HD
Strahlentherapie; 1975 Jan; 149(1):55-9. PubMed ID: 1124555
[TBL] [Abstract][Full Text] [Related]
23. Patients with differentiated thyroid cancer have a venous gradient in thyroglobulin levels.
Kebebew E; Reiff E
Cancer; 2007 Mar; 109(6):1078-81. PubMed ID: 17279579
[TBL] [Abstract][Full Text] [Related]
24. [Combined radioiodine (I131) treatment and radio-guided surgery for recurrent cervical well-differentiated thyroid cancer].
Schachter P; Shimonov M; Lorberboim M
Harefuah; 2005 Mar; 144(3):168-72, 232, 231. PubMed ID: 15844454
[TBL] [Abstract][Full Text] [Related]
25. Diagnostic whole-body scanning before radioiodine therapy for pulmonary metastases of differentiated thyroid cancer: predictive value and recommendations.
Tachi Y; Iwano S; Kato K; Tadokoro M; Naganawa S
Clin Nucl Med; 2008 Dec; 33(12):845-51. PubMed ID: 19033784
[TBL] [Abstract][Full Text] [Related]
26. The role of single-photon emission computed tomography/computed tomography for precise localization of metastases in patients with differentiated thyroid cancer.
Wang H; Fu HL; Li JN; Zou RJ; Gu ZH; Wu JC
Clin Imaging; 2009; 33(1):49-54. PubMed ID: 19135930
[TBL] [Abstract][Full Text] [Related]
27. High prevalence of side effects after recombinant human thyrotropin-stimulated radioiodine treatment with 30 mCi in patients with multinodular goiter and subclinical/clinical hyperthyroidism.
Romão R; Rubio IG; Tomimori EK; Camargo RY; Knobel M; Medeiros-Neto G
Thyroid; 2009 Sep; 19(9):945-51. PubMed ID: 19678745
[TBL] [Abstract][Full Text] [Related]
28. Incremental value of 131I SPECT/CT in the management of patients with differentiated thyroid carcinoma.
Chen L; Luo Q; Shen Y; Yu Y; Yuan Z; Lu H; Zhu R
J Nucl Med; 2008 Dec; 49(12):1952-7. PubMed ID: 18997044
[TBL] [Abstract][Full Text] [Related]
29. Clinical implication of F-18 FDG PET/CT for differentiated thyroid cancer in patients with negative diagnostic iodine-123 scan and elevated thyroglobulin.
Kim SJ; Lee TH; Kim IJ; Kim YK
Eur J Radiol; 2009 Apr; 70(1):17-24. PubMed ID: 18207685
[TBL] [Abstract][Full Text] [Related]
30. Bone metastases of differentiated thyroid cancer: impact of early 131I-based detection on outcome.
Hindié E; Zanotti-Fregonara P; Keller I; Duron F; Devaux JY; Calzada-Nocaudie M; Sarfati E; Moretti JL; Bouchard P; Toubert ME
Endocr Relat Cancer; 2007 Sep; 14(3):799-807. PubMed ID: 17914109
[TBL] [Abstract][Full Text] [Related]
31. Rare renal metastases from differentiated thyroid carcinoma: early clinical detection and treatment based on radioiodine.
Qiu ZL; Xue YL; Luo QY
Arq Bras Endocrinol Metabol; 2014 Apr; 58(3):260-9. PubMed ID: 24863088
[TBL] [Abstract][Full Text] [Related]
32. Bexarotene-induced hypothyroidism: bexarotene stimulates the peripheral metabolism of thyroid hormones.
Smit JW; Stokkel MP; Pereira AM; Romijn JA; Visser TJ
J Clin Endocrinol Metab; 2007 Jul; 92(7):2496-9. PubMed ID: 17440015
[TBL] [Abstract][Full Text] [Related]
33. Unusual case of well-differentiated papillary thyroid carcinoma lacking thyroglobulin expression while still concentrating radioiodine.
Singh B; Bollmann R; Ahmadzadehfar H; Biersack HJ; Ezziddin S
Br J Radiol; 2006 Sep; 79(945):e84-7. PubMed ID: 16940367
[TBL] [Abstract][Full Text] [Related]
34. [Use of 13-cis retinoic acid for treatment of advanced differentiated thyroid cancer].
Handkiewicz-Junak D; Roskosz J; Turska M; Wygoda Z; Jarzab B
Wiad Lek; 2001; 54 Suppl 1():301-6. PubMed ID: 12182039
[TBL] [Abstract][Full Text] [Related]
35. Patterns of relapse following radiotherapy for differentiated thyroid cancer: implication for target volume delineation.
Azrif M; Slevin NJ; Sykes AJ; Swindell R; Yap BK
Radiother Oncol; 2008 Oct; 89(1):105-13. PubMed ID: 18579244
[TBL] [Abstract][Full Text] [Related]
36. The influence of radioiodine therapy on the number of circulating epithelial cells (CEC) in patients with differentiated thyroid carcinoma - a pilot study.
Winkens T; Pachmann K; Freesmeyer M
Exp Clin Endocrinol Diabetes; 2014 Apr; 122(4):246-53. PubMed ID: 24771011
[TBL] [Abstract][Full Text] [Related]
37. Radioiodine therapy in patients with amiodarone-induced thyrotoxicosis (AIT).
Czarnywojtek A; Czepczynski R; Ruchala M; Wasko R; Zgorzalewicz-Stachowiak M; Szczepanek E; Zamyslowska H; Bartkowiak Z; Florek E; Sowinski J
Neuro Endocrinol Lett; 2009; 30(2):209-14. PubMed ID: 19675515
[TBL] [Abstract][Full Text] [Related]
38. Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma.
Hoftijzer H; Heemstra KA; Morreau H; Stokkel MP; Corssmit EP; Gelderblom H; Weijers K; Pereira AM; Huijberts M; Kapiteijn E; Romijn JA; Smit JW
Eur J Endocrinol; 2009 Dec; 161(6):923-31. PubMed ID: 19773371
[TBL] [Abstract][Full Text] [Related]
39. Open-label pilot study of combination therapy with rosiglitazone and bexarotene in the treatment of cutaneous T-cell lymphoma.
Sepmeyer JA; Greer JP; Koyama T; Zic JA
J Am Acad Dermatol; 2007 Apr; 56(4):584-7. PubMed ID: 17184879
[TBL] [Abstract][Full Text] [Related]
40. Insular thyroid carcinoma: collective analysis of clinicohistologic prognostic factors and treatment effect with radioiodine or radiation therapy.
Lai HW; Lee CH; Chen JY; Tseng LM; Yang AH
J Am Coll Surg; 2006 Nov; 203(5):715-22. PubMed ID: 17084334
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]